Tempus AI entered a multi‑year collaboration with Whitehawk Therapeutics to apply Tempus’ de‑identified multimodal real‑world dataset to Whitehawk’s ADC development programs. The partnership will analyze RNA and IHC concordance for ADC targets, prioritize indications with unmet need, and refine patient selection strategies for clinical trials. Whitehawk said the real‑world insights will inform indication choice and biomarker strategies to enrich responder populations for its ADC assets.